Glucagon-like peptide receptor-1 receptor agonists: The emerging fourth pillar in type 2 diabetes and chronic kidney disease?

被引：0
|
作者：
Ling, James [1 ]
Chow, Elaine [1 ,2 ]
机构：
[1] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Med & Therapeut, Hong Kong, Peoples R China
[2] Chinese Univ Hong Kong, Prince Wales Hosp, Phase Clin Trial Ctr 1, Hong Kong, Peoples R China
来源：
MED | 2024年 / 5卷 / 08期
关键词：
D O I：
10.1016/j.medj.2024.06.010
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
Previously, no randomized controlled trials investigated the renoprotective effects of glucagon-like peptide-1 receptor agonists (GLP-1RA) as the primary endpoint in patients with diabetes and chronic kidney disease. In the FLOW trial, Perkovic et al. showed that once-weekly semaglutide reduced kidney failure, kidneyrelated death, and cardiovascular death by 24% as compared with placebo in patients with type 2 diabetes at high risk of renal progression.
引用
收藏
页码：845 / 847
页数：3
相关论文
共 50 条
  • [11] The Role of Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes in Asia
    Lu, Ju-Ming
    ADVANCES IN THERAPY, 2019, 36 (04) : 798 - 805
  • [12] Emerging New Therapies for the Treatment of Type 2 Diabetes Mellitus: Glucagon-like Peptide-1 Receptor Agonists
    Lindamood, Christopher A.
    Taylor, James R.
    CLINICAL THERAPEUTICS, 2015, 37 (03) : 483 - 493
  • [13] Glucagon-like peptide 1 receptor agonists: a new approach to type 2 diabetes management
    Lambert, Lynn
    SOUTH AFRICAN FAMILY PRACTICE, 2013, 55 (06) : 511 - 514
  • [14] Review of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes mellitus in patients with chronic kidney disease and their renal effects
    Sloan, Lance A.
    JOURNAL OF DIABETES, 2019, 11 (12) : 938 - 948
  • [15] Use of glucagon-like peptide type 1 receptor agonists in kidney transplant recipients
    Vigara, Luis Alberto
    Villanego, Florentino
    Orellana, Cristhian
    Eady, Myriam
    Sanchez, Maria Gabriela
    Alonso, Marta
    Garcia, Maria Belen
    Amaro, Jose Manuel
    Garcia, Teresa
    Mazuecos, Auxiliadora
    NEFROLOGIA, 2024, 44 (06): : 885 - 893
  • [16] Effects of glucagon-like peptide-1 receptor agonists on kidney function and safety in type 2 diabetes patients
    Kim, Min Kyung
    Kim, Doo-Man
    JOURNAL OF DIABETES INVESTIGATION, 2021, 12 (06) : 914 - 916
  • [17] Novel Glucagon-like Peptide 1 Receptor Agonists for Treating Type II Diabetes
    Sabnis, Ram W.
    ACS MEDICINAL CHEMISTRY LETTERS, 2024, 15 (08): : 1182 - 1183
  • [18] Glucagon-like peptide-1 receptor agonists and kidney outcomes
    MacIsaac, Richard J.
    Trevella, Philippa
    Ekinci, Elif I.
    JOURNAL OF DIABETES, 2024, 16 (10)
  • [19] The Effect of Glucagon-Like Peptide-1 Receptor Agonists on Renal Outcomes in Type 2 Diabetes
    Win L. Yin
    Steve C. Bain
    Thinzar Min
    Diabetes Therapy, 2020, 11 : 835 - 844
  • [20] Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: Their Use and Differential Features
    Katherine A. Lyseng-Williamson
    Clinical Drug Investigation, 2019, 39 : 805 - 819
12345